JPRN-UMIN000013882已完成2 期
A Randomized, phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small-cell lung cancer HOT1401/NJCLG1401 - Randomized P2 ED SCLC maintenance CPT vs AMR
orth Japan Lung Cancer Study Group and Hokkaido Lung Cancer Clinical Study Group0 个研究点目标入组 80 人开始时间: 2014年6月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Clinically active interstitial pneumonia or pulmonary fibrosis, detectable on CT scan 2) History of heart disorder. 3) Severe co-morbidities (ex. uncontrolled heart or lung or hepatic or renal disease or diabetes) 4) Regular use of corticosteroid (less than 2 weeks interval after cessation) 5) Pregnancy or lactation, or those who decline contraception 6) Contraindication with chemotherapy 7) Active concomitant malignancy. Except carcinoma in situ or those who did not relapse 5-years or more 8) Those judged to be not suitable by the attending physician
研究者
相似试验
进行中（未招募）
1 期
Medical treatment for patients with cancer of the esophagus or stomachPatients with esophagus or gastric cancer and who are platinum resistant and non-resectabelMedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002321-30-DKOdense University Hospital
已完成
1 期
A multicenter phase I/II study of irinotecan (CPT-11) and S-1 combination chemotherapy for metastatic colorectal cancer (CRC)advanced/recurrent colorectal cancerJPRN-UMIN000001617CPT-11/TS-1 study group30
未知
Unknown
A randomized phase 2 trial of Irinotecan/Paclitaxel versus Irinotecan/Gemcitabine in patient with stage IIIB/IV non small cell lung cancer.JPRN-jRCT1080220109Yakult Honsha Co.,Ltd.
进行中（未招募）
不适用
A clinical trial to compare tolerabilty and efficiacy (how well the drug works) of following treatments:Blocking liver arteries (chemoembolisation) by beads loaded with irinotecan (chemotherapeutic) and intravenous administration of cetuximab (chemotherapeutic) compared to administration of intravenous cetuximab and irinotecan in patients with k-ras (gene) wild-type tumors.Patients with unresectable liver metastases of colorectal cancer who previously failed pretreatment with 5FU/oxaliplatin and/or 5FU/irinotecan (2nd- or 3rd-line).MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014728-44-DEMartin Luther Universität Halle-Wittenberg80
已完成
2 期
Randomized phase II trial of irinotecan(CPT-11) plus tegafur/uracil with oral leucovorin(UFT/LV) compared with FOLFIRI in patients with unresectable/recurrent colorectal cancerPatients with previously untreated and unresectable/recurrent colorectal cancerJPRN-UMIN000000951Department of Surgery, School of Medicine, Keio University72